Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease symbols : Gbt save search
Sickle Cell Disease Clinical Trial Pipeline Accelerates as 40+ Pharma Companies Rigorously Developing Drugs for the Market Entry
Published: 2023-07-11 (Crawled : 21:00) - prnewswire.com
DTIL | $9.81 -4.11% -4.28% 34K
|
Health Technology
|
| O: 1.57%
H: 19.67%
C: 9.97%
BLUE | $0.9274 -4.45% -4.66% 8.1M
|
Health Technology
|
| O: 2.2%
H: 0.27%
C: -1.62%
BLRX | $0.5966 -6.31% -6.74% 760K
|
Health Technology
|
| O: 0.0%
H: 2.94%
C: -0.59%
pharma disease companies pipeline cell trial market
Sickle Cell Disease Market to Observe Impressive Growth, Predicts DelveInsight | Key Companies Active in the Domain - Sanofi, Novartis, Vertex, CRISPR, Vifor, Pfizer, GlaxoSmithKline, Alexion, Global Blood
Published: 2023-05-22 (Crawled : 15:00) - prnewswire.com
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: 0.69%
H: 0.56%
C: -1.19%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
EDIT | News | $5.355 -1.92% -1.96% 1.6M
|
Health Technology
|
| O: -0.97%
H: 4.98%
C: 4.44%
BEAM | $22.74 -3.11% -3.21% 1.1M
|
Health Technology
|
| O: 0.2%
H: 2.51%
C: 1.56%
AGIO | $31.67 -0.44% -0.44% 540K
|
Health Technology
|
| O: 0.38%
H: 2.48%
C: 1.87%
disease companies active cell blood global market
Sickle Cell Disease Treatment Market to Garner USD 1.6 Billion by 2031: Allied Market Research
Published: 2022-11-10 (Crawled : 01:00) - prnewswire.com
EMMA | $0.0921 385.44% 66K
|
Professional, Scientific, and T...
|
| O: -18.92%
H: 15.0%
C: 15.0%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 2.81%
H: 0.43%
C: -0.2%
treatment research disease market
Folia Health Technology Platform Used in First-of-its-Kind Real World Evidence Study for Sickle Cell Disease
Published: 2022-09-15 (Crawled : 23:00) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -0.15%
H: 0.06%
C: -0.1%
disease health technology study platform
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
Published: 2022-09-15 (Crawled : 23:00) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -0.1%
H: 0.1%
C: -0.13%
treatment disease
MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
Published: 2022-07-26 (Crawled : 08:00) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -0.42%
H: 1.7%
C: -0.33%
oxbryta treatment disease anemia grants authorization
GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil
Published: 2022-07-14 (Crawled : 14:20) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -0.65%
H: 0.15%
C: -1.05%
disease brazil program
The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations
Published: 2022-07-13 (Crawled : 12:20) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -1.02%
H: 6.22%
C: 4.1%
awards disease grants
GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
Published: 2022-06-10 (Crawled : 08:00) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -6.01%
H: 0.0%
C: 0.0%
eha2022 oxbryta disease positive
GBT’s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease
Published: 2022-06-06 (Crawled : 16:00) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: 1.19%
H: 0.57%
C: -8.06%
gbt601 treatment fda rare drug disease designation
The GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and Institutions
Published: 2022-06-06 (Crawled : 14:20) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: 1.19%
H: 0.57%
C: -8.06%
disease grant program
European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older
Published: 2022-02-16 (Crawled : 12:00) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: 0.28%
H: 8.41%
C: 7.22%
oxbryta treatment europe anemia disease cel order
Positive Early Access to Medicines Scheme (EAMS) Scientific Opinion Awarded to GBT’s Voxelotor for the Treatment of Haemolytic Anaemia Due to Sickle Cell Disease
Published: 2022-01-27 (Crawled : 09:00) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: 1.7%
H: 2.15%
C: -4.75%
treatment disease cel positive
GBT’s Oxbryta® (voxelotor) Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older
Published: 2021-12-17 (Crawled : 17:00) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
oxbryta treatment anemia disease cel positive chmp order
GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and Exposition
Published: 2021-12-13 (Crawled : 15:30) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -12.83%
H: 0.0%
C: 0.0%
gbt0216 health disease positive results phase 1 positive results
GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition
Published: 2021-12-12 (Crawled : 16:20) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
| Email alert
Add to watchlist
oxbryta disease positive
GBT Supports the ASH Research Collaborative’s Data Hub Sickle Cell Disease ProgramGrant of $400,000 to help expand sickle cell disease real-world data gathering in the U.S.
Published: 2021-12-02 (Crawled : 15:00) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -5.32%
H: 6.45%
C: 6.25%
research disease
GBT Supports the ASH Research Collaborative's Data Hub Sickle Cell Disease Program
Published: 2021-12-02 (Crawled : 13:30) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -5.32%
H: 6.45%
C: 6.25%
research disease collaboration
GBT and Sickle Cell Disease Association of America to Host 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference
Published: 2021-09-08 (Crawled : 22:00) - globenewswire.com
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -0.2%
H: 2.96%
C: 0.6%
disease conference
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11
Published: 2021-09-07 (Crawled : 13:15) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: 1.23%
H: 1.51%
C: -2.39%
new drug disease treatment fda oxbryta children drug fda acceptance
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.